CCR8-depleting antibodies restore response to radiotherapy plus anti-PD1 therapy in head and neck cancer by targeting intratumoral CCR8+ regulatory T cells
Despite advances in immunotherapy (IO) and radiation therapy (RT), anti-PD-1 (aPD-1) therapy has provided only modest benefit in head and neck squamous cell carcinoma (HNSCC) for reasons that remain poorly understood. CCR8 is a chemokine receptor selectively enriched on tumor infiltrating regulatory T cells (Tregs), making it an attractive candidate for therapeutic targeting. Given our knowledge that immunosuppressive T-regulatory cells are associated with resistance to RT and IO, but have no effective targeting strategy in HNSCC, we investigate the depletion of tumor specific Treg subsets on tumor growth in female mice. In human and murine HNSCC, we characterize a subset of CCR8+ Tregs that are an immunosuppressive cell population associated with incomplete response to RT and IO. In preclinical models of HNSCC, we find that RT drives CCR8+ Treg infiltration into the primary tumor to promote tumor growth and recurrence, which can be reversed with administration of CCR8-depleting antibodies (aCCR8). Finally, we show that resistance to RT+aPD1 combination therapy is mediated by aPD1 activation of CCR8+ Tregs to facilitate tumor growth, which can be reversed with aCCR8. These findings reveal the immunosuppressive profile of CCR8+ Tregs in HNSCC and pave the way for novel combination strategies of IO in HNSCC. Previous evidence has implicated regulatory T cells (Tregs) in treatment resistance in head and neck cancer. Here the authors report that radiotherapy and anti-PD1 therapy drive the accumulation and activation of intratumoral CCR8+ Tregs, promoting tumor growth and recurrence, which can be reversed with administration of CCR8 depleting antibodies.
Authors
- Khalid N.M. Abdelazeem (ORCID: https://orcid.org/0000-0002-0672-7900)
- Sidharth V. Puram (ORCID: https://orcid.org/0000-0003-3543-889X)
- Sana D. Karam (ORCID: https://orcid.org/0000-0003-1676-5967)
- Brooke Neupert (ORCID: https://orcid.org/0009-0001-4379-3528)
- Nicholas A. Olimpo (ORCID: https://orcid.org/0000-0001-6556-2168)
- Jessica I. Beynor (ORCID: https://orcid.org/0000-0001-9430-0271)
- Jacob Gadwa (ORCID: https://orcid.org/0000-0003-0560-2337)
- Harshita Kumar
- Douglas Grant Osborne (ORCID: https://orcid.org/0000-0002-6772-7031)
- Benjamin Van Court (ORCID: https://orcid.org/0000-0001-5860-4489)
- Alexander Nguyen (ORCID: https://orcid.org/0000-0002-3968-4433)
- Nathan Pierce
- Joline Sun
- Andy Rankin
- Justin X. Yu
- Chloe Hodgson
- Tyler Weiskpof
- Michael Knitz
Institutions
- Amgen (United States) (US)
- Washington University in St. Louis (US)
- Egyptian Atomic Energy Authority (EG)
- University of Colorado Anschutz Medical Campus (US)
Publication Details
- Journal
- Nature Communications
- Published
- 2026-11-13
- DOI
- https://doi.org/10.1038/s41467-026-79341-8
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Harvard University
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institute of Dental and Craniofacial Research